Threshold effects of glucose transporter-4 (GLUT4) deficiency on cardiac glucose uptake and development of hypertrophy.

The aim of this study was to investigate the metabolic and structural consequences of a decrease in glucose transporter-4 (GLUT4) levels on the heart. The CreLoxP system was utilised to delete GLUT4 in muscle tIssue including heart. The presence of the PGK-neoR cassette in the GLUT4-Lox mice resulted in reduced expression in all tIssues to levels 15-30% of wild-type control mice. In mice expressing Cre recombinase, there was a further reduction of GLUT4 in cardiac tIssue to almost undetectable levels. Cardiac glucose uptake was measured basally and during a euglycaemic/hyperinsulinaemic clamp using 2-deoxy-[1-(14)C]glucose. Insulin-stimulated glucose uptake was normal in hearts expressing 15% of normal GLUT4 levels but markedly reduced in mice with more profound reduction in GLUT4. Cardiac enlargement occurred only when GLUT4 levels were less than 5% of normal values. In heart there is a threshold level of GLUT4 above which insulin-stimulated glucose uptake is maintained. As little as 5% of normal GLUT4 levels expressed in heart is sufficient to prevent the development of cardiac hypertrophy.

[1]  B. Carabello,et al.  Cardiac catheterization technique in a closed-chest murine model. , 2003, Contemporary topics in laboratory animal science.

[2]  C. Deng,et al.  Direct removal in the mouse of a floxed neo gene from a three‐loxp conditional knockout allele by two novel approaches , 2001, Genesis.

[3]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[4]  N. Makino,et al.  Determination of left ventricular mass by echocardiography in normotensive diabetic patients. , 2000, Japanese circulation journal.

[5]  R. Chalkley,et al.  Phosphoenolpyruvate Carboxykinase Is Necessary for the Integration of Hepatic Energy Metabolism , 2000, Molecular and Cellular Biology.

[6]  C. Kahn,et al.  Targeted disruption of the glucose transporter 4 selectively in muscle causes insulin resistance and glucose intolerance , 2000, Nature Medicine.

[7]  V. P. Chacko,et al.  Preservation of glucose metabolism in hypertrophic GLUT4-null hearts. , 2000, American journal of physiology. Heart and circulatory physiology.

[8]  L. Hennighausen,et al.  Bcl-x and Bax regulate mouse primordial germ cell survival and apoptosis during embryogenesis. , 2000, Molecular endocrinology.

[9]  Andras Nagy,et al.  Cre recombinase: The universal reagent for genome tailoring , 2000, Genesis.

[10]  B. Lowell,et al.  Cardiac hypertrophy with preserved contractile function after selective deletion of GLUT4 from the heart. , 1999, The Journal of clinical investigation.

[11]  J. Melki,et al.  Gene targeting restricted to mouse striated muscle lineage. , 1999, Nucleic acids research.

[12]  G. Martin,et al.  An Fgf8 mutant allelic series generated by Cre- and Flp-mediated recombination , 1998, Nature Genetics.

[13]  H. Parving,et al.  Left Ventricular Hypertrophy in Non‐insulin‐dependent Diabetic Patients With and Without Diabetic Nephropathy , 1997, Diabetic medicine : a journal of the British Diabetic Association.

[14]  A. Stenbit,et al.  Cardiac and adipose tissue abnormalities but not diabetes in mice deficient in GLUT4 , 1995, Nature.

[15]  A R Dunn,et al.  Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. , 1994, Blood.

[16]  E. Kraegen,et al.  Glucose transporters and in vivo glucose uptake in skeletal and cardiac muscle: fasting, insulin stimulation and immunoisolation studies of GLUT1 and GLUT4. , 1993, The Biochemical journal.

[17]  J. Dominguez,et al.  Effects of diabetes on myocardial glucose transport system in rats: implications for diabetic cardiomyopathy. , 1993, The American journal of physiology.

[18]  E. Hardeman,et al.  Quantitative analysis of the human alpha-skeletal actin gene in transgenic mice. , 1993, The Journal of biological chemistry.

[19]  J. Proietto,et al.  Cyclic AMP acutely stimulates translocation of the major insulin-regulatable glucose transporter GLUT4. , 1992, The Journal of biological chemistry.

[20]  R. Larkins,et al.  Evolution of Insulin Resistance in New Zealand Obese Mice , 1991, Diabetes.

[21]  J. Slot,et al.  Translocation of the glucose transporter GLUT4 in cardiac myocytes of the rat. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[22]  A. Folsom,et al.  Trends in Prevalence of Diabetes Mellitus in Patients with Myocardial Infarction and Effect of Diabetes on Survival: The Minnesota Heart Survey , 1991, Diabetes Care.

[23]  S. Factor,et al.  A comparison of the pathological spectrum of hypertensive, diabetic, and hypertensive-diabetic heart disease. , 1990, Circulation.

[24]  S. Litwin,et al.  Abnormal cardiac function in the streptozotocin-diabetic rat. Changes in active and passive properties of the left ventricle. , 1990, The Journal of clinical investigation.

[25]  J. Wisneski,et al.  Myocardial substrate utilization during exercise in humans. Dual carbon-labeled carbohydrate isotope experiments. , 1988, The Journal of clinical investigation.

[26]  L. Kedes,et al.  Multiple 5'-flanking regions of the human alpha-skeletal actin gene synergistically modulate muscle-specific expression , 1987, Molecular and cellular biology.

[27]  D. James,et al.  Heterogeneity of insulin action in muscle: influence of blood flow. , 1986, The American journal of physiology.

[28]  L. Shapiro,et al.  Left ventricular function in diabetes mellitus. I: Methodology, and prevalence and spectrum of abnormalities. , 1981, British heart journal.

[29]  S. Goldman,et al.  A role of fatty acid oxidation in cardiac hypertrophy. , 1993, Cardioscience.

[30]  S. Litwin,et al.  Chronic inhibition of fatty acid oxidation: new model of diastolic dysfunction. , 1990, The American journal of physiology.